Our dedicated R&D hub combines analytical chemistry, formulation design, and ICH stability testing to accelerate novel therapeutic solutions.
Equipped with state-of-the-art HPLC, LC-MS/MS, FTIR, and automated dissolution apparatus. Our research team focuses on developing bioequivalent generic formulations, controlled-release matrix systems, and taste-masked pediatric suspensions.
Utilizing computational solubility prediction, particle size reduction via jet milling, and bioavailability enhancement matrix design.
Collaborate on Research| Formulation Code | Therapeutic Area | Dosage Technology | Development Stage | Target Filing |
|---|---|---|---|---|
| FP-2026-ONC | Oncology | Targeted Liposomal Injection | Phase III Bioequivalence | Q4 2026 |
| FP-2026-CARD | Cardiology | Dual-Release Bilayer Tablet | Stability Testing | Q1 2027 |
| FP-2027-CNS | Neuroscience | Orally Disintegrating Strip | Formulation Optimization | Q2 2027 |